In this study, we investigated the mechanism of action of CPEB3 using a mice model of epilepsy. We found that CPEB3 was closely linked to epilepsy using bioinformatics analysis. CPEB3 was expressed at low levels in the brain tissues of patients with epilepsy and epileptic mouse models, and CPEB3 co-localized with neurons. CPEB3 overexpression in the hippocampus of mice reduced seizure susceptibility and severity, whereas CPEB3 knockdown increased the seizure susceptibility and severity. Further mechanistic studies revealed that CPEB3 inhibited STAT3 translation and STAT3-mediated transcriptional activity of NMDARs, thereby suppressing NMDAR subunit expression and attenuating epilepsy phenotype. Our findings provide a new theoretical basis for the pathogenesis of epilepsy.
The main pathological mechanisms underlying TLE include neural death, glial cell proliferation, and altered synaptic plasticity. The development of TLE is usually accompanied by cognitive dysfunction and memory impairment. CPEB3 is a key RBP that maintains long-term memory and synaptic plasticity(Qu et al. 2020; Si et al. 2010). However, whether CPEB3 plays a role in epilepsy has not yet been investigated. Our study found that the CPEB3 expression level was reduced in mice models and patients with TLE brain tissues. We also focused on the cellular localization of CPEB3 in brain tissues and found that CPEB3 was co-expressed in neurons. Next, behavioral tests revealed that CPEB3 overexpression attenuated seizures in mice. In contrast, CPEB3 knockdown exacerbated the seizure phenotype. In conclusion, CPEB3 is involved in the pathogenesis of epilepsy; however, the specific molecular mechanisms require further investigation.
The JAK/STAT pathway is involved in the pathogenesis of epilepsy by affecting various biological processes, including, synaptic plasticity, and ferroptosis (Chen et al. 2023; Ouyang et al. 2022; Xu et al. 2024). STAT3 is an important transcription factor, mainly located in the cytoplasm in the normal state, and p-STAT3 expression increases in the activated JAK/STAT pathway. Increased p-STAT3 induces the nuclear translocation of STAT3 and increases its binding to DNA, thereby affecting target gene transcription(Liu et al. 2024). Recently, researchers found that CPEB3 negatively regulates the activation of the JAK/STAT pathway(Zhong et al. 2020). Our study found that CPEB3 inhibited STAT3 and p-STAT3 in total protein extracts, cytoplasmic and nuclear extracts. Moreover, we found that CPEB3 did not alter STAT3 mRNA expression level. Therefore, we speculated that CPEB3 inhibits the translation of STAT3 by binding to STAT3 mRNA. Subsequent RIP experiments confirmed our speculation. This suggests that CPEB3 may alters the epilepsy phenotype by inhibiting the transcriptional activity of STAT3.
NMDARs are glutamate receptors widely distributed in the central nervous system and play an important role in brain development and synaptic plasticity(Goldsmith 2019; Mony et al. 2023; Wang et al. 2021; Zhou et al. 2021). NMDAR dysfunction can cause various central nervous system disorders, including schizophrenia, epilepsy, and Alzheimer's disease. Additional studies have shown that the expression and function of NMDARs are closely related to epilepsy(Sadeghi et al. 2021; Strehlow et al. 2019; Zhang et al. 2024). Excessive activation of NMDARs can cause neuronal depolarization and calcium overload, leading to neuronal death, and blocking NMDAR activation can reduce neuronal death(Ge et al. 2020). GluN1, GluN2A, and GluN2B are the main isoforms of NMDARs and are widely distributed in the cortex and hippocampus(Chen et al. 2021). Mutations in the gene encoding can lead to epilepsy(Sabo et al. 2022). In animal models of epilepsy, the expression of GluN1, GluN2A, and GluN2B subunits is increased(Postnikova et al. 2017). A nonspecific blocker of NMDARs-memantine can reduce the severity and susceptibility of epileptic mice(Gu et al. 2023). In our study, we found that CPEB3 can negatively regulate the mRNA expression levels of GluN1, GluN2A, and GluN2B in the hippocampus. The following results shown that in the hippocampus of epileptic mice, overexpression or knockdown of CPEB3 expression negatively regulated the protein expression of GluN1, GluN2A, and GluN2B in total protein lysates and cell membrane lysates in hippocampal tissues; it did not alter the protein expression of GluN1 and GluN2B in synaptosome lysates. We analyzed that this may be because the expression of GluN1 and GluN2B in hippocampal synapses is regulated by another mechanism.
In this study, we demonstrated that CPEB3 inhibited the activation of STAT3 by negatively regulating the translation of STAT3 and reducing the nuclear translocation of STAT3. This indicated that CPEB3 alters the transcription of STAT3 downstream target genes. Previous studies have disclosed that STAT3 is involved in regulating genes associated with synaptic plasticity(Tipton et al. 2023). Consequently, we speculated that CPEB3 can reduce STAT3-mediated transcription of NMDARs by inhibiting STAT3 translation. Next, we performed rescue experiments using WP1066, a specific inhibitor of STAT3. The results showed that the inhibition of STAT3 activation in mice with CPEB3 knockdown increased the expression of NMDARs and the mRNAs expression levels of GluN1, GluN2A, and GluN2B. CHIP experiments showed that STAT3 directly binds to the transcriptional promoters of GluN1, GluN2A, and GluN2B. Additionally, behavioral experiments demonstrated that WP1066 reduced the severity and susceptibility to epilepsy. These experimental results suggest that CPEB3 can reduce seizure severity and susceptibility in mice by inhibiting the STAT3-mediated transcription of NMDARs.
Our study has several limitations. First, we only confirmed the role of exogenous CPEB3 with STAT3 mRNA due to the lack of specific CPEB3 antibodies that can perform RIP. Second, our results showed that CPEB3 does not regulate GluN1 and GluN2B in hippocampal synaptic lysates, and the specific mechanism underlying this phenomenon must be further explored.
In conclusion, our experimental results suggest that CPEB3 can reduce STAT3-mediated transcription of NMDARs by inhibiting STAT3 translation, which attenuates the epileptic phenotype. These results provide new insights into the search for new therapeutic targets and pathogenesis of epilepsy.